Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases

Objective Pneumocystis pneumonia (PCP) is one of the most common opportunistic infections. In systemic autoimmune disease patients receiving immunosuppressive treatments, low lymphocyte count, old age and coexisting lung disease have been known as risk factors for the occurrence of PCP. However, factors relevant to prognosis of PCP have not been fully studied. Methods A total of 95 sequential patients who developed PCP during immunosuppressive treatment for systemic autoimmune diseases was identified from five Japanese centres. We retrospectively assessed baseline characteristics, immunosuppressive treatment prior to the onset of PCP, treatment for PCP and survival. Univariate and multivariate analyses were performed to identify prognostic factors. Results Forty-two deaths (44.2%) were observed in this study. Age at the diagnosis of PCP was higher in non-survivors than in survivors (74 years vs. 64 years, p = 0.008). Non-survivors more frequently had lung involvement than did survivors (47.6% vs. 13.2%, p<0.001). Median lymphocyte count at the diagnosis of PCP was lower in non-survivors than in survivors (499/μl vs. 874/μl, p = 0.002). Multivariate analysis identified lower lymphocyte count, older age and coexisting lung disease at the diagnosis of PCP as independent risk factors for death. Those risk factors for death were similar to the known risk factors for the occurrence of PCP. Conclusion Although PCP can occur even in patients without these risk factors, our data demonstrate that the overall prognosis of PCP in such patients is good. Given that the standard prophylactic treatment against PCP has safety issues, the risk-stratified use of prophylactic treatment may be advisable.

• Publication year

  2019

• Venue

  PLoS ONE

• Publication date

  2019-03-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1371/journal.pone.0214324PMID 30908547PMCID 6433250
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome

  2018cited by this paper
• Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?

  2017cited by this paper
• Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study.

  2017cited by this paper
• Pneumocystis jirovecci pneumonia in connective tissue diseases: Comparison with other immunocompromised patients.

  2015cited by this paper
• Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death

  2015cited by this paper
• Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection.

  2014cited by this paper
• Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals.

  2014cited by this paper
• Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study

  2014cited by this paper
• Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patients

  2012cited by this paper
• Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.

  2011cited by this paper
• Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and

  2009cited by this paper
• Pneumocystis pneumonia associated with infliximab in Japan.

  2007cited by this paper
• Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease

  2006cited by this paper
• Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature

  2006cited by this paper
• Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy

  2005cited by this paper
• Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

  2001cited by this paper
• Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients.

  1999cited by this paper
• Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia.

  1998cited by this paper
• (1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia

  1996cited by this paper
• Pneumocystis carinii Pneumonia: Differences in Lung Parasite Number and Inflammation in Patients with and without AIDS

  1989cited by this paper
• Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

  1984cited by this paper

• Risk Factors and Outcomes of Pneumocystis jirovecii pneumonia in Kidney Transplant Recipients: A Case-Control Study of the United States Renal Data System.

  2025cites this paper
• Pneumocystis jirovecii Pneumonia in Patients Without HIV, Transplant, or Cancer: Missed Opportunities for Prevention.

  2025cites this paper
• Low-dose atovaquone for prophylaxis of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases: an open-label, multicentre, single-arm, phase II trial

  2025cites this paper
• Comparison of the outcomes of Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients treated with and without biologics.

  2024cites this paper
• Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA)

  2024cites this paper
• Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: a global research network with a follow-up multicenter case-control study

  2023cites this paper
• Risk factors for Pneumocystis pneumonia with acute respiratory failure among kidney transplant recipients

  2023cites this paper
• Changing Trends in the Incidence and Clinical Features of Pneumocystis jirovecii Pneumonia in Non-HIV Patients before and during the COVID-19 Era and Risk Factors for Mortality between 2016 and 2022

  2023cites this paper
• Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study

  2023cites this paper
• Pneumocystis Pneumonia in Rheumatic Diseases: Prevention Issues

  2022cites this paper
• Outcomes and Risk Factors for Mortality in Pneumocystis Pneumonia Patients with Rheumatoid Arthritis: A Multicenter Retrospective Cohort Study.

  2022cites this paper
• Risk Factors of Mortality From Pneumocystis Pneumonia in Non-HIV Patients: A Meta-Analysis

  2021influential citation
• Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases

  2021cites this paper
• Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics

  2020cites this paper
• Pneumocystis pneumonia in a treatment-naive rheumatoid arthritis patient

  2019cites this paper